Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Research & Development (R&D) Day  (Replay)
    Thursday, December 06, 2018 12:00 pm EST
Toggle Summary Spring Bank Pharmaceuticals Names Nezam Afdhal, MD as Chief Medical Officer
MILFORD, Mass., November 9, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that Nezam Afdhal, MD, will join the Company as Chief Medical Officer, effective November 9, 2015.
Toggle Summary Spring Bank Pharmaceuticals Announces Presentation of Results from Phase I Clinical Trial Supporting the Novel Mechanism of Action of SB 9200 in Patients with Hepatitis C at The Liver Meeting®
MILFORD, Mass., October 13, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that a poster presentation describing results from a Phase 1 clinical trial of SB 9200 in patients
Toggle Summary Spring Bank Pharmaceuticals Appoints Martin Driscoll as President and Chief Executive Officer – Kurt M. Eichler Elected to the Board of Directors
MILFORD, Mass., August 17, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced the appointment of Martin Driscoll as President and Chief Executive Officer. Mr.
Toggle Summary Spring Bank Pharmaceuticals Presents Preclinical and Clinical Data on Immunomodulatory Agent SB 9200 at the 2015 Annual Meeting of the European Association for the Study of the Liver
Animal Efficacy Studies in Chronically-Infected Woodchucks and Clinical Trial Results in Hepatitis C Patients Provide Support for Targeting RIG-I and NOD2 Sentinel Proteins to Restore Host Antiviral Defense MILFORD, Mass., April 27, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage
Toggle Summary Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015
MILFORD, Mass., April 13, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced two poster presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B Virus
Toggle Summary Spring Bank Pharmaceuticals to Present Novel Approach to Hepatitis B Treatment at the 2015 AASLD and Industry Colloquium
MILFORD, Mass. – March 12, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of hepatitis B and other viral infections, today announced that Radhakrishnan P. (Kris) Iyer, Ph.D., Chief Scientific Officer of Spring
Toggle Summary Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance
MILFORD, Mass., February 26, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of virus infections, today announced that Jonathan P. Freve, CPA, has been appointed Vice President of Finance, a newly created role. Mr.
Toggle Summary Spring Bank Pharmaceuticals Completes $22 Million Financing – Proceeds to Support Phase II Clinical Development of SB 9200 Against Hepatitis B
MILFORD, Mass., February 26, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of Hepatitis B virus (HBV) and other viral infections, today announced the closing of a $22 million financing.
Toggle Summary Spring Bank Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
MILFORD, Mass., Jan. 28, 2015 — Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced that Douglas J. Jensen, President and CEO, will present at the 17(th) annual BIO CEO & Investor
Toggle Summary Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens
MILFORD, Mass. – September 18, 2014 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RNA viruses, today announced a research collaboration with the National Institutes of Health (NIH) for animal testing of the